• Basilea highlighted a partnership-led, asset-light anti-infectives model built around hospital brands Cresemba and Zevtera.
• Cresemba marketed in 76 countries; moving annual total sales of USD 782 million for April 2025 to March 2026, up 27% year-on-year.
• Zevtera U.S. launch in July 2025 via Innoviva Specialty Therapeutics; U.S. market exclusivity runs until April 2034.
• Phase 3 pipeline centered on fosmanogepix in invasive candidiasis and invasive mold infections, supported by expanded-access use in 500+ patients.
• Ceftibuten-ledaborbactam positioned as an oral option for resistant Gram-negative cUTI; Phase 3 initiation targeted for early 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Basilea Pharmaceutica AG published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.